Accelerating Innovation at Leica Biosystems

Life Sciences Overview -$14.5B TOTAL REVENUE 2021E Revenue By Mix Nonrecurring Recurring cytiva PALL Leica XXIDT BECKMAN COULTER Life Sciences SCIEX Ophenomenex INTEGRATED DNA TECHNOLOGIES MICROSYSTEMS GLOBAL GROWTH DRIVERS aldevron MOLECULAR DEVICES Increasing focus on genomic medicine . Shift towards biologics By Geography By End-Market ROW Clinical Rsrch./ Acad. . NA . HGM W. EU Ind. Biopharma Applied • All financial metrics reflect FY 2021E results from continuing operations; all pie chart percentages are % of 2021E revenues. Vaccine, therapeutics & research in response to COVID-19 HGM investments in basic & applied research capacity Strong global brands with leading market positions DANAHER

View entire presentation